Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy

Despite recent advances in diagnosis and treatment, invasive mould infections (IMIs) are an important cause of morbidity and mortality globally, particularly in immunocompromised individuals [1]. The incidence of invasive aspergillosis (IA), the most common IMI, is 10 –20 cases per 1 million population overall, with an incidence of 0.2–0.6% in intensive care units (ICUs), 0.5–3.9% following haematopoietic stem cell transplant (HSCT) and 0.1–2.4% following solid-organ transplantation (SOT) [2]. Reported mortality rates from IA range from 30% to 60% at 12 w eeks in patients with an underlying haematological malignancy, HSCT, SOT or solid tumour and 41% at 12 months in SOT patients [1–3].

Source: International Journal of Antimicrobial Agents - August 9, 2018 Category: Drugs & Pharmacology Authors: Jeffrey D. Jenks, Sharon L. Reed, Danila Seidel, Philipp Koehler, Oliver A. Cornely, Sanjay R. Mehta, Martin Hoenigl Tags: Short Communication Source Type: research